{
  "id": 20389032,
  "title": "Novofactory Receives Flawless FDA Assessment",
  "url": "https://urgent.news/2026/11/17/novofactory-receives-flawless-fda-assessment",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-17T06:16:51.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=281508"
  },
  "original_language": "en",
  "account": "CG Bio, a regenerative medicine company, recently received a flawless assessment from the FDA for its Novofactory facility in Hwaseong, Gyeonggi Province. The on-site inspection, conducted between the end of August and early September, scrutinized the facility's human tissue operations in compliance with regulations for Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P). Key inspection areas included the quality management system, donor eligibility verification for human tissues like bone and skin, raw material control, processing, storage, distribution, and traceability management. The FDA issued an official Establishment Inspection Report (EIR) on October 28, confirming no observations and no deficiencies recorded under FDA-483. Previously, CG Bio's Hyangnam S-Campus obtained AATB certification in 2021 and secured recertification in 2024. Novofactory, set for completion in March, is a complex manufacturing facility designed for human tissue processing and bioregenerative medicine device production. CG Bio leveraged its existing tissue bank's quality management expertise directly into Novofactory's production system. With allograft exports to the U.S. ongoing, the flawless inspection is expected to bolster local business expansion and strengthen partnerships with U.S. entities. CG Bio's CEO, Yu Hyun-seung, highlighted this as a testament to the company's advanced human tissue processing technology and quality management, asserting continued efforts to align production systems with global regulatory standards to accelerate U.S. market entry and global collaborations.",
  "summary": "CG Bio, a regenerative medicine company, said its Novofactory facility in Hwaseong, Gyeonggi Province, concluded an on-site FDA inspection of human tissue operations with zero findings. During the inspection, which was conducted from at the end of August to early September, the FDA closely reviewed",
  "key_points": [
    "FDA gave CG Bio's Novofactory facility a flawless assessment in September.",
    "Inspection covered quality management, donor verification, and traceability.",
    "Novofactory set for completion in March will boost business and partnerships."
  ],
  "editors_take": "The flawless inspection validates CG Bio's quality management systems and clears a significant regulatory path for the company to expand its allograft exports and strengthen partnerships within the United States.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}